
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/642917/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. American Journal of Psychiatry, 2018, 175, 225-231.	4.0	441
2	Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice, 2012, 16, 77-84.	1.2	327
3	Blood-brain barrier permeability and physical exercise. Journal of Neuroinflammation, 2019, 16, 15.	3.1	148
4	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	1.7	107
5	The Influence of Antidepressants on the Immune System. Archivum Immunologiae Et Therapiae Experimentalis, 2019, 67, 143-151.	1.0	70
6	Seizure following sudden zolpidem withdrawal. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 539-540.	2.5	67
7	Prevalence of self-reported insomnia in general population of Poland. Psychiatria Polska, 2016, 50, 165-173.	0.2	62
8	Factors associated with depression in Parkinson's disease: a cross-sectional study in a Polish population. European Psychiatry, 2006, 21, 516-520.	0.1	47
9	Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. World Journal of Biological Psychiatry, 2021, 22, 1-15.	1.3	38
10	C-reactive protein and cortisol in drug-naÃ ⁻ ve patients with short-illness-duration first episode major depressive disorder: Possible role of cortisol immunomodulatory action at early stage of the disease. Journal of Affective Disorders, 2014, 152-154, 534-537.	2.0	34
11	The Brain–Skin Axis in Psoriasis—Psychological, Psychiatric, Hormonal, and Dermatological Aspects. International Journal of Molecular Sciences, 2022, 23, 669.	1.8	34
12	The role of melatonin and melatonin receptor agonist in the prevention of sleep disturbances and delirium in intensive care unit – a clinical review. Sleep Medicine, 2020, 69, 127-134.	0.8	32
13	Perspectives for therapy of treatmentâ€resistant depression. British Journal of Pharmacology, 2022, 179, 4181-4200.	2.7	30
14	Prevalence of anxiety disorders in epilepsy. Epilepsy and Behavior, 2018, 79, 1-3.	0.9	29
15	Wilson's disease associated with delusional disorder. Psychiatry and Clinical Neurosciences, 2006, 60, 758-760.	1.0	28
16	Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects. British Journal of Clinical Pharmacology, 2008, 65, 444-445.	1.1	27
17	Therapeutic drug monitoring of atypical antipsychotics Psychiatria Polska, 2017, 51, 1059-1077.	0.2	26
18	Validation of the Hospital Anxiety and Depression Scale in patients with epilepsy. Epilepsy and Behavior, 2016, 58, 97-101.	0.9	24

#	Article	IF	CITATIONS
19	World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. International Journal of Psychiatry in Clinical Practice, 2015, 19, 2-7.	1.2	23
20	Ketogenic diet for depression: A potential dietary regimen to maintain euthymia?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110257.	2.5	23
21	Severe skin complications in patients treated with antidepressants: aÂliterature review. Postepy Dermatologii I Alergologii, 2014, 2, 92-97.	0.4	22
22	<p>Ketamine in Bipolar Disorder: A Review</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2707-2717.	1.0	22
23	Tianeptine Abuse and Dependence in Psychiatric Patients: A Review of 18 Case Reports in the Literature. Journal of Psychoactive Drugs, 2018, 50, 275-280.	1.0	21
24	Ketogenic diet for schizophrenia: Nutritional approach to antipsychotic treatment. Medical Hypotheses, 2018, 118, 74-77.	0.8	21
25	Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. European Journal of Clinical Pharmacology, 2010, 66, 955-955.	0.8	20
26	Role of copper in depression. Relationship with ketamine treatment. Medical Hypotheses, 2018, 119, 14-17.	0.8	20
27	Psychometric properties and diagnostic utility of the State–Trait Anxiety Inventory in epilepsy with and without comorbid anxiety disorder. Epilepsy and Behavior, 2019, 92, 221-225.	0.9	20
28	Peripheral blood lymphocyte subpopulations in patients with bipolar disorder type II. Scientific Reports, 2019, 9, 5869.	1.6	20
29	Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders. International Journal of Molecular Sciences, 2021, 22, 8623.	1.8	20
30	Antidepressants in epilepsy. Neurologia I Neurochirurgia Polska, 2018, 52, 657-661.	0.6	19
31	Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2637-2646.	1.0	19
32	Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression. Frontiers in Psychiatry, 2021, 12, 704330.	1.3	19
33	Validation of the Polish version of the Hospital Anxiety and Depression Scale for anxiety disorders in patients with epilepsy. Epilepsy and Behavior, 2018, 84, 162-165.	0.9	18
34	Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis. Medicina (Lithuania), 2020, 56, 67.	0.8	17
35	Expert advice on the management of valproate in women with bipolar disorder at childbearing age. European Neuropsychopharmacology, 2019, 29, 1199-1212.	0.3	16
36	Psychological Functioning of Patients Undergoing Oral Surgery Procedures during the Regime Related with SARS-CoV-2 Pandemic. Journal of Clinical Medicine, 2020, 9, 3344.	1.0	15

#	Article	IF	CITATIONS
37	Gut Microbiota in Depression: A Focus on Ketamine. Frontiers in Behavioral Neuroscience, 2021, 15, 693362.	1.0	15
38	Antipsychotic drugs in epilepsy. Neurologia I Neurochirurgia Polska, 2019, 53, 408-412.	0.6	15
39	Reevaluating the prevalence and diagnostic subtypes of depressive disorders in epilepsy. Epilepsy and Behavior, 2015, 53, 15-19.	0.9	14
40	Copper and anti-anhedonic effect of ketamine in treatment-resistant depression. Medical Hypotheses, 2020, 144, 110268.	0.8	14
41	Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy. Psychiatria Danubina, 2017, 29, 345-348.	0.2	14
42	Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. Psychiatria Danubina, 2019, 31, 585-590.	0.2	14
43	Interictal dysphoric disorder of epilepsy: A continuing diagnostic challenge. Epilepsy and Behavior, 2019, 95, 34-38.	0.9	13
44	Quetiapine abuse and dependence in psychiatric patients: a systematic review of 25 case reports in the literature. Journal of Substance Use, 2014, 19, 388-393.	0.3	12
45	Validation of the Polish version of the Beck Depression Inventory in patients with epilepsy. Epilepsy and Behavior, 2017, 77, 58-61.	0.9	12
46	Clozapine in Treatment-Resistant Bipolar Disorder With Suicidality. Three Case Reports. Frontiers in Psychiatry, 2019, 10, 520.	1.3	12
47	Efficacy of Ketamine in bipolar depression: focus on anhedonia. Psychiatria Danubina, 2019, 31, 554-560.	0.2	12
48	Low baseline salivary alpha-amylase in drug-naÃ ⁻ ve patients with short-illness-duration first episode major depressive disorder. Journal of Affective Disorders, 2014, 157, 14-17.	2.0	11
49	Clozapine As Transformative Treatment In Bipolar Patients. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2901-2905.	1.0	11
50	Do sleep changes mediate the antiâ€depressive and antiâ€suicidal response of intravenous ketamine in treatmentâ€resistant depression?. Journal of Sleep Research, 2022, 31, e13400.	1.7	11
51	Magnesium, C-reactive protein, and cortisol in drug-naÃ ⁻ ve patients with short illness-duration, first episode major depressive disorder: possible immunomodulatory role for magnesium. Magnesium Research, 2016, 29, 169-174.	0.4	10
52	<p>Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2539-2551.	1.0	10
53	Ketogenic Diet: A Dietary Modification as an Anxiolytic Approach?. Nutrients, 2020, 12, 3822.	1.7	10
54	Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study. Medicine (United States), 2021, 100, e26769.	0.4	10

#	Article	IF	CITATIONS
55	A cry for help, do not omit the signs. Dermatitis artefacta – psychiatric problems in dermatological diseases (a review of 5 cases). Medical Science Monitor, 2012, 18, CS85-CS89.	0.5	10
56	A retrospective study of DRESS – drug reaction with eosinophilia and systemic symptoms. Psychiatria Polska, 2017, 51, 1079-1093.	0.2	9
57	Heart rate variability and incidence of depression during the first six months following first myocardial infarction. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1951-1956.	1.0	8
58	Mechanisms of action of the ketogenic diet in depression. Neuroscience and Biobehavioral Reviews, 2019, 107, 422-423.	2.9	8
59	Ketamine and Lamotrigine Combination in Psychopharmacology: Systematic Review. Cells, 2022, 11, 645.	1.8	8
60	Validation of the Polish Version of the Hamilton Rating Scale for Depression in patients with epilepsy. Epilepsy and Behavior, 2016, 62, 81-84.	0.9	7
61	The neurobiology of addiction. A vulnerability/resilience perspective. European Journal of Psychiatry, 2018, 32, 139-148.	0.7	7
62	Recommendations of the Polish Psychiatric Association regarding the treatment of affective disorders in women of childbearing age. Part II: Bipolar disorder. Psychiatria Polska, 2019, 53, 263-276.	0.2	7
63	Dermatitis artefactaa long way from the first clinical symptoms to diagnosis. Psychiatria Danubina, 2011, 23, 73-5.	0.2	7
64	Somatic Comorbidities and Cardiovascular Safety in Ketamine Use for Treatment-Resistant Depression. Medicina (Lithuania), 2021, 57, 274.	0.8	6
65	Psychogenic axial myoclonus: report on two cases. Neurological Sciences, 2010, 31, 219-222.	0.9	5
66	Sleep Related Amnestic Behaviors due to Zolpidem. Journal of Microbiology and Biotechnology, 2014, 24, 188-194.	0.9	5
67	Psychometric properties of the Polish version of the Hamilton Anxiety Rating Scale in patients with epilepsy with and without comorbid anxiety disorder. Epilepsy and Behavior, 2019, 94, 9-13.	0.9	5
68	Copper Concentrations in Ketamine Therapy for Treatment-Resistant Depression. Brain Sciences, 2020, 10, 971.	1.1	5
69	Affective Switch Associated With Oral, Low Dose Ketamine Treatment in a Patient With Treatment Resistant Bipolar I Depression. Case Report and Literature Review. Frontiers in Psychiatry, 2020, 11, 516.	1.3	5
70	Multiple Comorbidity Profile of Psychiatric Disorders in Epilepsy. Journal of Clinical Medicine, 2021, 10, 4104.	1.0	5
71	Promazine in the treatment of delusional parasitosis. Psychiatria Danubina, 2011, 23, 198-9.	0.2	5
72	Magnesium in drug-naÃ ⁻ ve patients with a short-duration, first episode of major depressive disorder: impact on psychopathological features. Magnesium Research, 2013, 26, 192-198.	0.4	4

#	Article	IF	CITATIONS
73	Ketamine and magnesium common pathway of antidepressant action. Magnesium Research, 2018, 31, 33-38.	0.4	4
74	Screening and diagnosis for mood and anxiety disorders in epilepsy: Polish population reference values. Neurologia I Neurochirurgia Polska, 2021, 55, 351-356.	0.6	4
75	Recommendations of the Polish Psychiatric Association for treatment of affective disorders in women of childbearing age. Part III: Approach to pregnancy loss and unsuccessful in vitro treatment of infertility Psychiatria Polska, 2019, 53, 277-292.	0.2	4
76	Dysphoria and Irritability—Diagnostic Pitfalls in the Assessment of Interictal Dysphoric Disorder in Epilepsy. Journal of Clinical Medicine, 2021, 10, 4624.	1.0	4
77	Cortisol as an indicator of hypothalmic-pitituary-adrenal axis dysregulation in patients with panic disorder: a literature review. Psychiatria Danubina, 2015, 27 Suppl 1, S445-51.	0.2	4
78	Neurosyphilis presenting with depressive symptomatology: is it unusual?. Acta Neuropsychiatrica, 2008, 20, 110-110.	1.0	3
79	Dependence on zolpidem: Is pharmacokinetics important?. Psychiatry and Clinical Neurosciences, 2008, 62, 127-127.	1.0	3
80	Low baseline salivary 3-methoxy-4-hydroxyphenylglycol (MHPG) in drug-naÃ ⁻ ve patients with short-illness-duration first episode major depressive disorder. Journal of Affective Disorders, 2014, 161, 4-7.	2.0	3
81	17.1 A RANDOMIZED CONTROLLED TRIAL OF CANNABIDIOL IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S27-S27.	2.3	3
82	Overlapping phenomena of bipolar disorder and epilepsya common pharmacological pathway. Psychiatria Danubina, 2015, 27 Suppl 1, S177-81.	0.2	3
83	Refractory schizophrenia treated with clozapine combined with zuclopenthixol. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 781-783.	2.5	2
84	What really is a â€~gold standard' in depression recognition among patients with epilepsy?. Epilepsy and Behavior, 2018, 87, 249.	0.9	2
85	Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532110110.	1.2	2
86	No relationship between baseline salivary alpha-amylase and State-Trait Anxiety Inventory Score in drug-naive patients with short-illness-duration first episode major depressive disorder: An exploratory study. Journal of Clinical and Experimental Dentistry, 2017, 9, 0-0.	0.5	2
87	Commentary concerning treatment of depression in patients with heart failure according to 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 2140-2141.	0.8	2
88	Prolactin response to buspirone is not impaired in drug-naÃ⁻ve first episode patients with major depressive disorder. Journal of Affective Disorders, 2014, 152-154, 468-473.	2.0	1
89	Diagnosis of psychiatric comorbidities in epilepsy — The role of screening tools. Epilepsy and Behavior, 2019, 101, 106266.	0.9	1
90	Magnesium in Ketamine Administration in Treatment-Resistant Depression. Pharmaceuticals, 2021, 14, 430.	1.7	1

#	Article	IF	CITATIONS
91	The role of eugeroics in the treatment of affective disorders. Psychiatria Polska, 2020, 54, 21-33.	0.2	1
92	Zinc, C-reactive protein, and cortisol in major depressive disorder: an exploratory analysis. Trace Elements and Electrolytes, 2017, 34, 104-106.	0.1	1
93	Neuropsychiatric presentation of Sjögren syndrome. Polish Archives of Internal Medicine, 2019, 130, 68-69.	0.3	1
94	Mood disorders in epilepsy - diagnostic and methodological considerations. Psychiatria Danubina, 2012, 24 Suppl 1, S44-50.	0.2	1
95	Zinc in drug-naÃ ⁻ ve patients with short-illness-duration first episode major depressive disorder: impact on psychopathological features. Neuroendocrinology Letters, 2014, 35, 741-5.	0.2	1
96	Role of copper and ketamine in major depressive disorder - an update. Psychiatria Danubina, 2019, 31, 520-523.	0.2	1
97	Case Report: Repeated Series of Ketamine Infusions in Patients With Treatment-Resistant Depression: Presentation of Five Cases. Frontiers in Psychiatry, 2021, 12, 705190.	1.3	1
98	Cortisol awakening response in drug-naïve panic disorder. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 1581-1585.	1.0	0
99	Impulsivity in drug-naÃ ⁻ ve panic disorder. European Journal of Psychiatry, 2017, 31, 45-49.	0.7	0
100	Letter to Editor regarding "Characterizing and predicting rates of delirium across general hospital settings― General Hospital Psychiatry, 2018, 53, 80-81.	1.2	0
101	Depression among patients with epilepsy — A diagnostic approach. Epilepsy and Behavior, 2018, 88, 396.	0.9	0
102	Commentary on: Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness, and neurocognitive performance in healthy volunteers. European Neuropsychopharmacology, 2021, 49, 38-39.	0.3	0
103	Factores asociados con la depresión en la enfermedad de Parkinson: un estudio transversal en una población polaca. European Psychiatry (Ed Española), 2007, 14, 129-134.	0.0	0
104	An overview of interventions in drug-induced weight gain during clozapine treatment. Psychiatria I Psychologia Kliniczna, 2015, 15, 76-80.	0.3	0
105	The use of antiepileptic drugs in the prevention of clozapine-induced seizures. Literature review. Psychiatria I Psychologia Kliniczna, 2015, 15, 71-75.	0.3	0
106	Cardiovascular and metabolic side effects of second-generation antipsychotics - narrative review. European Journal of Translational and Clinical Medicine, 2019, 2, 70-77.	0.0	0
107	Clinical considerations of sleep related amnestic behaviours associated with zolpidem. Pharmacotherapy in Psychiatry and Neurology, 2020, 36, 23-31.	0.1	0
108	Salivary 5-hydroxyindole acetic acid (5-HIAA) in drug-naÃ ⁻ ve patients with short-illness-duration first episode major depressive disorder. Neuroendocrinology Letters, 2014, 35, 746-9.	0.2	0